Shopping Cart

There are no products in your cart.

Dr Ingrid Burvenich

POSTDOCTORAL RESEARCH FELLOW

More about Dr Ingrid Burvenich

The ongoing objective of my work is to image and improve drug delivery and efficacy in cancer patients.

After finishing my PhD in Ghent, I joined the Ludwig Insitute for Cancer Research as a postdoctoral research fellow to further my expertise in antibody characterization, antibody engineering and pre-clinical in vitro and in vivo evaluation of antibodies. My postdoctoral studies at Ludwig focused on the Fc domain engineering of an anti-Lewis Y antibody (hu3S193) to optimize the pharmacokinetic properties for payload strategies such as radioimmunotherapy and enhance activation of immune effector functions. In parallel, I have been pivotally involved in the preclinical development of two antibodies developed with academic collaborators and licensed to start-up companies, as well as four antibodies in collaboration with pharmaceutical companies. My preclinical molecular imaging investigations directly contributed to two of these antibodies entering Phase I bioimaging human trials (NCT01220999, NCT02252211).

In addition to the development of the licensed antibodies and new pharma preclinical collaborations, my current research focuses on identifying and developing novel strategies for targeted therapy of cancer in patients with a poor clinical outcome (these cancers include triple negative breast cancer (TNBC) and glioblastoma (GBM)), as well as for cancer patients with cachexia. I am collaborating with La Trobe University on a project that is exploring better and safer treatments for osteosarcoma, and with SAHMRI on a project exploiting alterations in lipid metabolism in order to improve diagnosis, treatment and molecular imaging of prostate cancer. With a background in bio-engineering and pharmaceutical sciences, I am passionate about combining molecular imaging and targeted therapies in facilitating a fast translation of discoveries from bench to clinic for the benefit of patients.